Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Inhibitors of Bacterial Protein Synthesis

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...

The Proteasome Structure

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nanomechanical Phenotyping of Circulating Tumor Cells with Atomic Force Microscopy.

Methods in molecular biology (Clifton, N.J.)·2026

Same author

Model Circulating Tumor Cells Induced by Mechanical Stress.

Methods in molecular biology (Clifton, N.J.)·2026

Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

CTC1-STN1-TEN1 controls DNA break repair pathway choice via DNA end resection blockade.

Science (New York, N.Y.)·2025

Same author

Proteasome Augmentation Mitigates Age-Related Cognitive Decline in Mice.

Aging cell·2025

Search research articles

Related Experiment Video

Updated: May 11, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Rapamycin allosterically inhibits the proteasome.

Pawel A Osmulski¹, Maria Gaczynska

¹University of Texas Health Science Center at San Antonio, Department of Molecular Medicine, Institute of Biotechnology, 15355 Lambda Drive, San Antonio, TX 78245, USA.

Molecular Pharmacology

|April 27, 2013

Summary

Rapamycin, an mTOR inhibitor, also regulates the proteasome by inhibiting its activity and affecting substrate binding. This suggests new therapeutic strategies targeting the proteasome with rapamycin analogs.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Related Experiment Videos

Last Updated: May 11, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Area of Science:

Biochemistry
Molecular Biology
Pharmacology

Background:

Rapamycin is a known inhibitor of the mammalian target of rapamycin (mTOR) kinase, exhibiting immunosuppressive and proapoptotic effects.
The proteasome is a critical intracellular protease complex responsible for protein degradation via the ubiquitin-proteasome pathway.

Purpose of the Study:

To investigate the effects of rapamycin on proteasome function in vitro.
To explore the potential of rapamycin and its analogs as modulators of proteasome activity.

Main Methods:

In vitro assays measuring proteinase and peptidase activities of the 20S proteasome core.
Analysis of the binding interactions between rapamycin, proteasome activators (19S cap, PA200), and the 20S proteasome core.
Conformational dynamics studies of the proteasomal gate upon rapamycin treatment.

Main Results:

Rapamycin inhibits proteinase and peptidase activities of the 20S proteasome core at low micromolar concentrations.
Rapamycin interferes with the binding of the 19S cap and PA200 activator to the 20S proteasome core.
Rapamycin alters the conformational dynamics of the proteasomal gate, impacting substrate entry.

Conclusions:

Rapamycin and its analogs, including seco-rapamycin, target the proteasome by binding to its α face, allosterically affecting its function.
These findings suggest a dual mechanism of action for rapamycin, impacting both mTOR and proteasome pathways.
The study provides a basis for designing novel allosteric drugs targeting the proteasome for therapeutic purposes.